Pete Sr - Catalyst Pharmaceuticals Vice Sales
| CPRX Stock | USD 22.07 0.27 1.21% |
Executive
Pete Sr is Vice Sales of Catalyst Pharmaceuticals
| Address | 355 Alhambra Circle, Coral Gables, FL, United States, 33134 |
| Phone | 305 420 3200 |
| Web | https://www.catalystpharma.com |
Catalyst Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.1835 % which means that it generated a profit of $0.1835 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2829 %, meaning that it created $0.2829 on every $100 dollars invested by stockholders. Catalyst Pharmaceuticals' management efficiency ratios could be used to measure how well Catalyst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.27 in 2024. Return On Capital Employed is likely to rise to 0.23 in 2024. At this time, Catalyst Pharmaceuticals' Return On Assets are fairly stable compared to the past year. Asset Turnover is likely to rise to 0.89 in 2024, whereas Other Assets are likely to drop 0.95 in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Melita Jung | Terns Pharmaceuticals | 47 | |
| John SullivanBolyai | Hepion Pharmaceuticals | 76 | |
| Sheila Denton | Incyte | 58 | |
| Benir Ruano | ACADIA Pharmaceuticals | N/A | |
| Michael Morrissey | Incyte | 60 | |
| Patrick Mayo | Hepion Pharmaceuticals | N/A | |
| Ben Strain | Incyte | N/A | |
| Diane Berry | Sarepta Therapeutics | N/A | |
| Brian JD | Madrigal Pharmaceuticals | 62 | |
| Douglas MD | ACADIA Pharmaceuticals | 62 | |
| Mary Jenkins | Sarepta Therapeutics | N/A | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| PharmD MBA | Incyte | 66 | |
| Jeffrey JD | Exelixis | 55 | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Laura Dillard | Exelixis | N/A | |
| Dana Aftab | Exelixis | 60 | |
| Frank Yocca | BioXcel Therapeutics | 68 | |
| Michael Morneau | Viking Therapeutics | 59 | |
| Adam JD | Day One Biopharmaceuticals | 57 | |
| Paula Swain | Incyte | 66 | |
Management Performance
| Return On Equity | 0.28 | ||||
| Return On Asset | 0.18 |
Catalyst Pharmaceuticals Leadership Team
Elected by the shareholders, the Catalyst Pharmaceuticals' board of directors comprises two types of representatives: Catalyst Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catalyst. The board's role is to monitor Catalyst Pharmaceuticals' management team and ensure that shareholders' interests are well served. Catalyst Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catalyst Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Philip Schwartz, Co Sec | ||
| CMA CPA, VP, Officer | ||
| Pete Sr, Vice Sales | ||
| Richard MBA, CEO President | ||
| Mary Coleman, VP Relations | ||
| Stanley MD, Senior Discovery | ||
| Gary MD, Chief Officer | ||
| Jeffrey Carmen, Executive Officer | ||
| Michael CPA, Executive CFO | ||
| Preethi Sundaram, Chief Officer | ||
| Patrick McEnany, Co-Founder, Chairman, CEO and Pres | ||
| Steven Miller, COO and Chief Scientific Officer | ||
| Brian JD, Chief Officer |
Catalyst Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catalyst Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.28 | ||||
| Return On Asset | 0.18 | ||||
| Profit Margin | 0.31 % | ||||
| Operating Margin | 0.40 % | ||||
| Current Valuation | 2.23 B | ||||
| Shares Outstanding | 119.27 M | ||||
| Shares Owned By Insiders | 5.98 % | ||||
| Shares Owned By Institutions | 81.90 % | ||||
| Number Of Shares Shorted | 5.68 M | ||||
| Price To Earning | 23.62 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.